IL6 and atherosclerosis: The cardiovascular risk presented by DNMT3A- and TET2-mutant CHIP can be mitigated by an inhibitory IL-6 receptor gene variant (IL6R p.Asp358Ala) [43], highlighting the key role of the mediators of inflammation NLRP3, IL-1β and IL6 in CHIP-associated atherosclerosis.